Thanks.
It is worth noting the below as this is quite important for likelihood of success of dosing and readouts for the AML trials. Simplistically the historic data is like a crystal ball for the results to come.
In AML, Bisantrene achieved complete responses rates 40% to 72% range (average 52%) as a single-agent in 5 out 5 historic Phase II trials (1987 to 1994) .
Even with effectively half the number of cycles ( no consolidation course given ), the Israel trial that finished in 2020 achieved a 40% response rate ( effectively with half the drug given ). This was the reduction in tumour size in that 2020 trial.
![]()
The above result mid 2020 plus the release of the Cancer Cell paper about 10 days later drove a 269% rerate in the share price over a 1 month period.
![]()
- Forums
- ASX - By Stock
- RAC - Charts & Price Action
Thanks. It is worth noting the below as this is quite important...
-
- There are more pages in this discussion • 15,832 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.61 |
Change
0.000(0.00%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.61 | $1.66 | $1.61 | $200.5K | 123.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 26610 | $1.60 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.62 | 9717 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2131 | 1.605 |
7 | 29110 | 1.600 |
2 | 3171 | 1.595 |
2 | 31950 | 1.590 |
2 | 10950 | 1.585 |
Price($) | Vol. | No. |
---|---|---|
1.620 | 290 | 1 |
1.625 | 8447 | 2 |
1.630 | 6754 | 3 |
1.635 | 2015 | 2 |
1.640 | 12000 | 1 |
Last trade - 14.13pm 29/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |